{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:55:01Z","timestamp":1785704101893,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:33:02Z","timestamp":1779319982000},"page":"562-573.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"26","author":[{"given":"Anush A.","family":"Ginosyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Ashouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6689-8916","authenticated-orcid":false,"given":"Sophie","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-7144","authenticated-orcid":false,"given":"Elaine","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7995-6062","authenticated-orcid":false,"given":"Brian","family":"Hom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Nittur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-2476","authenticated-orcid":false,"given":"Blake","family":"Adnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2430-6613","authenticated-orcid":false,"given":"Mollee","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-8099","authenticated-orcid":false,"given":"Brandon","family":"Ann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Humayun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3455-1324","authenticated-orcid":false,"given":"Arsine","family":"Kolanjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Baya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preet","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8083-9639","authenticated-orcid":false,"given":"Imran","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karrune","family":"Woan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Leon","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6988-3556","authenticated-orcid":false,"given":"George","family":"Yaghmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2026.05.005_bib0001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/asheducation-2018.1.137","article-title":"Genetics and prognosis of ALL in children vs adults","volume":"2018","author":"Roberts","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.clml.2026.05.005_bib0002","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.05.005_bib0003","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-016-0519-8","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia in adults","volume":"18","author":"Ronson","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.clml.2026.05.005_bib0004","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.05.005_bib0005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"10299","key":"10.1016\/j.clml.2026.05.005_bib0006","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.clml.2026.05.005_bib0007","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2026.05.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101485","article-title":"The current landscape: allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia","volume":"36","author":"Prockop","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.05.005_bib0009","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.clml.2026.05.005_bib0010","first-page":"520.e1-e12","article-title":"Pretransplant blinatumomab improves outcomes in B cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation","volume":"30","author":"Sayyed","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.clml.2026.05.005_bib0011","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2026.05.005_bib0012","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/hematology.2024000533","article-title":"Transplant in ALL: who, when, and how?","volume":"2024","author":"Marcoux","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.clml.2026.05.005_bib0013","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute lymphoblastic leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.clml.2026.05.005_bib0014","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.05.005_bib0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bjh.17646","article-title":"Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation","volume":"194","author":"Nakamura","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.05.005_bib0016","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2026.05.005_bib0017","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.05.005_bib0018","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.clml.2022.12.009","article-title":"Efficacy and safety of Blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia: a systemic review and meta-analysis","volume":"23","author":"Liu","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"10.1016\/j.clml.2026.05.005_bib0019","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.05.005_bib0020","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2026.05.005_bib0021","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.05.005_bib0022","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2026.05.005_bib0023","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.05.005_bib0024","article-title":"Measurable residual disease detection in B-acute lymphoblastic leukemia: the children's Oncology Group (COG) method","volume":"2","author":"Borowitz","year":"2022","journal-title":"Curr Protoc"},{"issue":"1","key":"10.1016\/j.clml.2026.05.005_bib0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cyto.b.21482","article-title":"A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia\/lymphoma post anti-CD19 therapy","volume":"94","author":"Cherian","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2026.05.005_bib0026","article-title":"Concordance of next-generation sequencing and multiparametric flow cytometry methods for detecting measurable residual disease in adult acute lymphoblastic leukemia: optimizing prediction of clinical outcomes from a single-center study","author":"Ashouri","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147124","article-title":"An update on outcomes using the USC ALL frontline regimen (based on CCG-1882) after further modification of protocol in the era of novel agents in ph-negative ALL patients; a retrospective study","volume":"138","author":"Mendiola","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.05.005_bib0028","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0889-8588(05)70192-1","article-title":"The hyper-CVAD regimen in adult acute lymphocytic leukemia","volume":"14","author":"Garcia-Manero","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"8","key":"10.1016\/j.clml.2026.05.005_bib0029","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jtct.2022.05.010","article-title":"Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia in the modern era","volume":"28","author":"Liang","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.clml.2026.05.005_bib0030","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1111\/bjh.19771","article-title":"Philadelphia-like B-cell acute lymphoblastic leukaemia: disease features and outcomes in the era of immunotherapy","volume":"205","author":"Ashouri","year":"2024","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2026.05.005_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14062055","article-title":"Integrating Blinatumomab in the frontline treatment in B-cell acute lymphoblastic leukemia: a new era in therapeutic management","volume":"14","author":"Canichella","year":"2025","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.clml.2026.05.005_bib0032","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/COC.0000000000001179","article-title":"Impact of minimal residual diseases status and depth of response on survival outcomes in blinatumomab-treated acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"48","author":"Jamil","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2026.05.005_bib0033","series-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Sureda","year":"2024"},{"issue":"25","key":"10.1016\/j.clml.2026.05.005_bib0034","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.05.005_bib0035","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41409-021-01279-w","article-title":"Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data","volume":"56","author":"Badar","year":"2021","journal-title":"Bone Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:20:30Z","timestamp":1785702030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001485"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}